On Thursday, Following U.S. Stocks were among the “Top Gainers”: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Lumber Liquidators Holdings, Inc. (NYSE:LL), 2U, Inc. (TWOU), Lion Biotechnologies, Inc. (NASDAQ:LBIO)
Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC), with shares inclined 11.28%, closed at $1.08.
Lumber Liquidators Holdings Inc(NYSE:LL), with shares jumped 10.24%, settled at $36.08.
2U Inc(NASDAQ:TWOU), with shares climbed 9.98%, and closed at $21.15.
Lion Biotechnologies Inc(NASDAQ:LBIO), surged 9.93%, and closed at $12.40.
Latest NEWS regarding these Stocks are depicted underneath:
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)
Formerly on March 4, Cyclacel Pharmaceuticals, Inc. (CYCC), declared that it has priced its formerly declared public offering of 10,000,000 shares of its ordinary stock, at a price to the public of $1.00 per share, for gross proceeds of $10.0 million. The offering is predictable to close on March 9, 2015, subject to customary closing conditions.
The net proceeds, after deducting placement agent fees and expenses and other estimated fees and expenses payable by the Corporation, are about $9.2 million. The Corporation intends to use the proceeds from this offering for the continued clinical development of its most advanced product candidate, sapacitabine, in myelodysplastic syndromes (MDS) and other indications, Phase 1 clinical trials of its cyclin dependent kinase (CDK) inhibitor, CYC065, and general corporate purposes.
H.C. Wainwright & Co., LLC is acting as the sole book runner for the offering.
Cyclacel is a biopharmaceutical corporation developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine, Cyclacel’s most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has accomplished enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for myelodysplastic syndromes (MDS) and chronic lymphocytic leukemia (CLL).
Lumber Liquidators Holdings, Inc. (NYSE:LL)
Lumber Liquidators Holdings, Inc. (LL), the largest specialty retailer of hardwood flooring in North America, has successfully implemented its expanded showroom concept as the Corporation continues growing its nationwide footprint.
The Corporation presently has more than 350 stores within 46 states and Canada after opening 34 new stores and remodeling 17 existing stores in 2014. Presently, nearly a third of the store locations have implemented the expanded showroom and that number will continue to rise throughout the next several years.
All new and remodeled Lumber Liquidators stores are now designed around an improved customer shopping experience. Expanded showrooms and improved warehouse design allow stores to offer a larger assortment of flooring options, moldings, accessories and tools. A variety of floors are also installed so customers can walk on different styles and species of wood.
For ease of flooring comparison and selection, products are grouped by category and displayed within color palettes and cost. Shoppers can also take home free flooring samples and consult with Lumber Liquidators flooring experts at every turn.
Robert M. Lynch, President and Chief Executive Officer, commented, “Customers are telling us that the new store concept is making floor shopping easier. Combining this with our high-quality flooring and legendary low prices creates consumer demand that continues fueling our expansion plans.”
Lumber Liquidators Holdings, Inc., together with its auxiliaries, operates as a multi-channel specialty retailer of hardwood flooring, and hardwood flooring enhancements and accessories.
2U, Inc. (TWOU)
2U, Inc. (TWOU), declared that it is partnering with Yale University to launch an online Master of Medical Science (MMSc) degree for aspiring physician associates (PA), pending approval of the online program by the Accreditation Review Commission on Education for the Physician Assistant (ARC-PA) and various state licensing agencies.
The program will enable online students to receive the same high-quality training as their on-campus counterparts without the financial burden and stress of relocating, while also encouraging PAs to learn and work in their local communities. In contrast with most PA programs, the online program also will recruit student cohorts three times per year instead of one, allowing qualified students to start their education and training as soon as they are ready.
Leveraging 2U’s leading cloud-based software-as-a-service platform, the online PA program will comprise: collaborative, live classes that facilitate face-to-face interaction; high-quality, interactive coursework developed by Yale faculty who teach in the program; in addition to hands-on clinical experience at field sites chosen with each student’s location and career aims in mind. The program also will feature in-person immersion experiences that allow students to collaborate with classmates and professors on-site at the Yale campus in New Haven, CT.
According to the Bureau of Labor Statistics, job opportunities for Physician Assistants are predictable to raise by 38 percent between 2012 and 2022. This equates to an additional 33,300 new positions, driven by heightened demand for health care services from older patients, raised prevalence of chronic disease and a shortage of primary care physicians. The career website Glassdoor also ranked Physician Assistant at #1 in its list of the “25 Best Jobs in America for 2015,” based on earnings potential, career opportunities and number of job openings.
Offering many of the health care services offered by physicians, PAs take patient histories and perform physical exams, diagnose illnesses and develop treatment plans, order lab tests and prescribe medications, counsel and educate patients, and, in surgical settings, suture wounds and assist in surgery, among other responsibilities.
2U, Inc., partners with leading colleges and universities to deliver the world’s best online degree programs so students everywhere can reach their full potential. Our cloud-based software-as-a-service platform provides schools with the comprehensive operating infrastructure they need to attract, enroll, educate, support and graduate students globally.
Lion Biotechnologies, Inc. (NASDAQ:LBIO)
Formerly on March 3, Lion Biotechnologies, Inc. (LBIO), declared the closing of its underwritten public offering of 9,200,000 shares of its ordinary stock at $8.00 per share, counting 1,200,000 shares sold following the exercise in full of the underwriters’ option to purchase additional shares, resulting in gross proceeds from the offering of $73.6 million, before deducting underwriting discounts and commissions and offering expenses payable by Lion.
Lion intends to use the net proceeds of the offering for the development of its product candidates, counting its planned Phase 2 clinical trial for metastatic melanoma, and for other general corporate and working capital purposes.
Jefferies LLC, Cowen and Corporation, LLC and Piper Jaffray & Co. acted as the joint book-running managers of the offering, and Roth Capital Partners, LLC acted as co-manager.
Lion Biotechnologies, Inc. is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The corporation’s lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for the treatment of patients with Stage 4 metastatic melanoma, and is based on a clinical Cooperative Research and Development Contract with the National Cancer Institute.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
